Top

Published in:

01-07-2017 | SSIEM 2016

What is new in CDG?

Authors: Jaak Jaeken, Romain Péanne

Published in: Journal of Inherited Metabolic Disease | Issue 4/2017

Abstract

Congenital disorders of glycosylation (CDG) are one group among the disorders of glycosylation. The latter comprise defects associated with hypoglycosylation but also defects with hyperglycosylation. Genetic diseases with hypoglycosylation can be divided in primary congenital disorders of glycosylation (CDG) and in genetic diseases causing secondary hypoglycosylation. This review covers the human CDG highlights from the last 3 years (2014–2016) following a summary of the actual status of CDG. It expands on 23 novel CDG namely defects in SLC39A8, CAD, NANS, PGM3, SSR4, POGLUT1, NUS1, GANAB, PIGY, PIGW, PIGC, PIGG, PGAP1, PGAP3, VPS13B, CCDC115, TMEM199, ATP6AP1, ATP6V1A, ATP6V1E1, TRAPPC11, XYLT1 and XYLT2. Besides, it discusses novel phenotypes of known CDG (DHDDS-CDG, ALG9-CDG, EXT2-CDG, PIGA-CDG, PIGN-CDG), the elucidation of putative glycosyltransferase disorders as O-mannosylglycan synthesis disorders (TMEM5-CDG, ISPD-CDG, FKTN-CDG, FKRP-CDG), a novel CDG mechanism, advances in diagnosis, pathogenesis, treatment and finally an updated list of the 104 known CDG.

Aeby A, Prigogine C, Vilain C, Malfilatre G, Jaeken J, Lederer D, Van Bogaert P (2016) RFT1-congenital disorder of glycosylation (CDG): a cause of early-onset severe epilepsy. Epileptic Disord 18:92–96PubMed

AlSubhi S, AlHashem A, AlAzami A et al (2015) Further delineation of the ALG9-CDG phenotype. JIMD Rep 27:107–112CrossRefPubMedPubMedCentral

Argov Z, Caraco Y, Lau H et al (2016) Aceneuramic acid extended release administration maintains upper limb muscle strength in a 48-week study of subjects with GNE myopathy: results from a phase 2, randomized, controlled study. J Neuromuscul Dis 3:49–66CrossRefPubMedPubMedCentral

Barone R, Fiumara A, Jaeken J (2014) Congenital disorders of glycosylation with emphasis on cerebellar involvement. Semin Neurol 34:357–366CrossRefPubMed

Basmanav FB, Oprisoreanu AM, Pasternack SM et al (2014) Mutations in POGLUT1, encoding protein O-glucosyltransferase 1, cause autosomal-dominant Dowling-Degos disease. Am J Hum Genet 94:135–143CrossRefPubMedPubMedCentral

Bengtson P, Ng BG, Jaeken J, Matthijs G, Freeze HH, Eklund EA (2016) Serum transferrin carrying the xeno-tetrasaccharide NeuAc-gal-GlcNAc2 is a biomarker of ALG1-CDG. J Inherit Metab Dis 39:107–114CrossRefPubMed

Bögershausen N, Shahrzad N, Chong JX et al (2013) Recessive TRAPPC11 mutations cause a disease spectrum of limb girdle muscular dystrophy and myopathy with movement disorder and intellectual disability. Am J Hum Genet 93:181–190CrossRefPubMedPubMedCentral

Boycott KM, Beaulieu CL, Kernohan KD et al (2015) Autosomal-recessive intellectual disability with cerebellar atrophy syndrome caused by mutation of the manganese and zinc transporter gene SLC39A8. Am J Hum Genet 97:886–893CrossRefPubMedPubMedCentral

Buczkowska A, Swiezewska E, Lefeber DJ (2015) Genetic defects in dolichol metabolism. J Inherit Metab Dis 38:157–169CrossRefPubMed

Chiyonobu T, Inoue N, Morimoto M, Kinoshita T, Murakami Y (2014) Glycosylphosphatidylinositol (GPI) anchor deficiency caused by mutations in PIGW is associated with west syndrome and hyperphosphatasia with mental retardation; syndrome. J Med Genet 51:203–207CrossRefPubMed

Climer LK, Dobretsov M, Lupashin V (2015) Defects in the COG complex and COG-related trafficking regulators affect neuronal Golgi function. Front Neurosci. doi:10.3389/fnins.2015.00405 PubMedPubMedCentral

Dörre K, Olczak M, Wada Y et al (2015) A new case of UDP-galactose transporter deficiency (SLC35A2-CDG): molecular basis, clinical phenotype, and therapeutic approach. J Inherit Metab Dis 38:931–940CrossRefPubMed

Duplomb L, Duvet S, Picot D et al (2014) Cohen syndrome is associated with major glycosylation defects. Hum Mol Genet 23:2391–2399CrossRefPubMed

Edvardson S, Murakami Y, Nguyen TTM et al (2016) Mutations in the phosphatidylinositol glycan C (PIGC) gene are associated with epilepsy and intellectual disability. J Med Genet. doi:10.1136/jmedgenet-2016-104202 PubMedCentral

Farhan SMK, Wang J, Robinson JF et al (2015) Old gene, new phenotype: mutations in heparan sulfate synthesis enzyme, EXT2 leads to seizure and developmental disorder, no exostoses. J Med Genet 52:666–675CrossRefPubMed

Fauth C, Steindl K, Toutain A et al (2016) A recurrent germline mutation in the PIGA gene causes Simpson-Golabi-Behmel syndrome type 2. Am J Med Genet Part A 170A:392–402CrossRefPubMed

Freeze HH, Chong JX, Bamshad MJ, Ng BG (2014) Solving glycosylation disorders: fundamental approaches reveal complicated pathways. Am J Hum Genet 94:161–175CrossRefPubMedPubMedCentral

Freeze HH, Eklund EA, Ng BG, Patterson MC (2015) Neurological aspects of human glycosylation disorders. Ann Rev Neurosci 38:105–125CrossRefPubMedPubMedCentral

Gerin I, Ury B, Breloy I et al (2016) ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto α-dystroglycan. Nat Commun. doi:10.1038/ncomms11534 PubMedPubMedCentral

Guo L, Elcioglu NH, Iida A et al (2016) Novel and recurrent XYLT1 mutations in two Turkish families with Desbuquois dysplasia, type 2. J Hum Genet. doi:10.1038/jhg.2016.143

Gupta S, Fahiminiya S, Wang T et al (2016) Somatic overgrowth associated with homozygous mutations in both MAN1B1 and SEC23A. Cold Spring Harb Mol Case Stud. doi:10.1101/mcs.a000737 PubMedPubMedCentral

Hennet T, Cabalzar J (2015) Congenital disorders of glycosylation: a concise chart of glycocalyx dysfunction. Trends Biochem Sci 40:377–384CrossRefPubMed

Höck M, Wegleiter K, Ralser E et al (2015) ALG8-CDG: novel patients and review of the literature. Orphanet J Rare Dis 10:73. doi:10.1186/s13023-015-0289-7 CrossRefPubMedPubMedCentral

Hogrebe M, Murakami Y, Wild M et al (2016) A novel mutation in PIGW causes glycosylphosphatidylinositol deficiency without hyperphosphatasia. Am J Med Genet Part A 170A:3319–3322CrossRef

Ilkovski B, Pagnamenta AT, O'Grady GL et al (2015) Mutations in PIGY: expanding the phenotype of inherited glycosylphosphatidylinositol deficiencies. Hum Mol Genet 24:6146-6159

Jaeken J, Morava E (2016) Congenital disorders of glycosylation, dolichol and glycosylphosphatidylinositol metabolism. In: Saudubray J-M, Baumgartner MR, Walter J (eds) Inborn metabolic diseases diagnosis and treatment, Chap. 41, 6th edn. Springer, Berlin

Jaeken J, Hennet T, Matthijs G, Freeze HH (2009) CDG nomenclature: time for a change! Biochim Biophys Acta 1792:825–826CrossRefPubMedPubMedCentral

Jansen JC, Cirak S, van Scherpenzeel M et al (2016a) CCDC115 deficiency causes a disorder of Golgi homeostasis with abnormal protein glycosylation. Am J Hum Genet 98:310–321CrossRefPubMedPubMedCentral

Jansen JC, Timal S, van Scherpenzeel M et al (2016b) TMEM199 deficiency is a disorder of Golgi homeostasis characterized by elevated aminotransferases, alkaline phosphatase, and cholesterol and abnormal glycosylation. Am J Hum Genet 98:322–330CrossRefPubMedPubMedCentral

Jansen EJR, Timal S, Ryan M et al (2016c) ATP6AP1 deficiency causes an immunodeficiency with hepatopathy, cognitive impairment and abnormal protein glycosylation. Nat Commun. doi:10.1038/ncomms11600

Kanagawa M, Kobayashi K, Tajiri M et al (2016) Identification of a post-translational modification with ribitol-phosphate and its defect in muscular dystrophy. Cell Rep 14:2209–2223CrossRefPubMed

van Karnebeek CDM, Bonafé L, Wen X-Y et al (2016) NANS-mediated synthesis of sialic acid is required for brain and skeletal development. Nat Genet 48:777–784CrossRefPubMed

Kettwig M, Elpeleg O, Wegener E et al (2016) Compound heterozygous variants in PGAP1 causing severe psychomotor retardation, brain atrophy, recurrent apneas and delayed myelination: a case report and literature review. BMC Neurol 16:74CrossRefPubMedPubMedCentral

Kimizu T, Takahashi Y, Oboshi T et al (2016) A case of early onset epileptic encephalopathy with de novo mutation in SLC35A2: clinical features and treatment for epilepsy. Brain and Development. doi:10.1016/j.braindev.2016.09.009 PubMed

Knaus A, Awaya T, Helbig I et al (2016) Rare noncoding mutations extend the mutational spectrum in the PGAP3 subtype of hyperphosphatasia with mental retardation syndrome. Hum Mutat 37:737–744CrossRefPubMedPubMedCentral

Koch J, Mayr JA, Alhaddad B et al (2017) CAD mutations and uridine-responsive epileptic encephalopathy. Brain 140(Pt 2):279–286

Kodera H, Nakamura K, Osaka H et al (2013) De novo mutations in SLC35A2 encoding a UDP-galactose transporter cause early-onset epileptic encephalopathy. Hum Mutat 34:1708–1714CrossRefPubMed

Koehler K, Milev MP, Prematilake K et al (2017) A novel TRAPPC11 mutation in two Turkish families associated with cerebral atrophy, global retardation, scoliosis, achalasia and alacrima. J Med Genet 54:176–185CrossRefPubMed

Kouwenberg D, Gardeitchik T, Mohamed M, Lefeber DJ, Morava E (2014) Wrinkled skin and fat pads in patients with ALG8-CDG: revisiting skin manifestations in congenital disorders of glycosylation. Pediatr Dermatol 31:e1–e5CrossRefPubMed

Krasnewich D (2014) Human glycosylation disorders. Cancer Biomark 14:3–16CrossRefPubMed

Lam C, Ferreira C, Krasnewich D et al (2016) Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation. Genet Med. doi:10.1038/gm.2016.75 (Epub ahead of print)

Lee JK, Kim H, Park YM, Kim DH, Lim HT (2017) Mutations in DZIP1 and XYLT1 are associated with nonsyndromic early onset high myopia in the Korean population. Ophthalmic Genet. doi:10.1080/13816810.2016.1232415

Liang W-C, Zhu W, Mitsuhashi S et al (2015) Congenital muscular dystrophy with fatty liver and infantile-onset cataract caused by TRAPPC11 mutations: broadening of the phenotype. Skelet Muscle 5:29. doi:10.1186/s13395-015-0056-4 n CrossRefPubMedPubMedCentral

Losfeld ME, Ng BG, Kircher M et al (2014) A new congenital disorder of glycosylation caused by a mutation in SSR4, the signal sequence receptor 4 protein of the TRAP complex. Hum Mol Genet 23:1602–1605CrossRefPubMed

Lundin KE, Hamasy A, Backe PH et al (2015) Susceptibility to infections, without concomitant hyper-IgE, reported in 1976, is caused by hypomorphic mutation in the phosphoglucomutase 3 (PGM3) gene. Clin Immunol 161:366–372CrossRefPubMedPubMedCentral

Makrythanasis P, Kato M, Zaki MS et al (2016) Pathogenic variants in PIGG cause intellectual disability with seizures and hypotonia. Am J Hum Genet 98:615–626CrossRefPubMedPubMedCentral

Manya H, Yamaguchi Y, Kanagawa M et al (2016) The muscular dystrophy gene TMEM5 encodes a ribitol β1-4 xylosyltransferase required for the functional glycosylation of dystroglycan. J Biol Chem 291:24618–24627CrossRefPubMedPubMedCentral

Matalonga L, Bravo M, Serra-Peinado C et al (2017) Mutations in TRAPPC11 are associated with a congenital disorder of glycosylation. Hum Mut 38:148–151CrossRefPubMed

McInerney-Leo AM, Harris JE, Gattas M et al (2016) Fryns syndrome associated with recessive mutations in PIGN in two separate families. Hum Mutat 37:695–702CrossRefPubMed

Mohamed M, Cantagrel V, Al-Gazali L, Wevers RA, Lefeber DJ, Morava E (2011) Normal glycosylation screening does not rule out SRD5A3-CDG. Eur J Hum Genet 19:1019. doi:10.1038/ejhg.2010.260 CrossRefPubMedPubMedCentral

Monticelli M, Ferro T, Jaeken J, Dos Reis FV, Videira PA (2016) Immunological aspects of congenital disorders of glycosylation (CDG): a review. J Inherit Metab Dis 39:765–780CrossRefPubMed

Morava E (2014) Galactose supplementation in phosphoglucomutase-1 deficiency: review and outlook for a novel treatable CDG. Mol Genet Metab 112:275–279CrossRefPubMedPubMedCentral

Morava E, Tiemes V, Thiel C et al (2016) ALG6-CDG: a recognizable phenotype with epilepsy, proximal muscle weakness, ataxia and behavioural and limb anomalies. J Inher Metab Dis 39:759CrossRefPubMed

de la Morena-Barrio ME, Martínez-Martínez I, De Cos C et al (2016) Hypoglycosylation is a common finding in antithrombin deficiency in the absence of a SERPINC1 gene defect. J Thromb Haemost 14:1549–1560CrossRefPubMed

Ng BG, Buckingham KJ, Raymond K et al (2013) Mosaicism of the UDP-galactose transporter SLC35A2 causes a congenital disorder of glycosylation. Am J Hum Genet 92:632–636CrossRefPubMedPubMedCentral

Ng BG, Raymond K, Kircher M et al (2015a) Expanding the molecular and clinical phenotype of SSR4-CDG. Hum Mut 36:1048–1051CrossRefPubMedPubMedCentral

Ng BG, Wolfe LA, Ichikawa M et al (2015b) Biallelic mutations in CAD impair de novo pyrimidine biosynthesis and decrease glycosylation precursors. Hum Mol Genet 24:3050–3057CrossRefPubMedPubMedCentral

Park EJ, Grabinska KA, Guan Z et al (2014) Mutation of Nogo-B receptor, a subunit of cis-prenyltransferase, causes a congenital disorder of glycosylation. Cell Metab 20:448–457CrossRefPubMedPubMedCentral

Park JH, Hogrebe M, Grüneberg M et al (2015) SLC39A8 deficiency: a disorder of manganese transport and glycosylation. Am J Hum Genet 97:894–903CrossRefPubMedPubMedCentral

Porath B, Gainullin VG, Cornec-Le Gall et al (2016) Mutations in GANAB, encoding the glucosidase IIa subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet 98:1193-1207

Praissman JL, Willer T, Sheikh MO et al (2016) The functional O-mannose glycan on α-dystroglycan contains a phospho-ribitol primed for matriglycan addition. elife 5:e14473. doi:10.7554/eLife.14473 CrossRefPubMedPubMedCentral

Riemersma M, Froese DS, van Tol W et al (2015) Human ISPD is a cytidyltransferase required for dystroglycan O-mannosylation. Chem Biol 22:1643–1652

Rymen D, Jaeken J (2014) Skin manifestations in CDG. J Inherit Metab Dis 37:699–708CrossRefPubMed

Sabry S, Vuillaumier-Barrot S, Mintet E et al (2016) A case of fatal type I congenital disorder of glycosylation (CDG-I) associated with low dehydrodolichol diphosphate synthase (DHDDS) activity. Orphanet J Rare Dis 11:84CrossRefPubMedPubMedCentral

Sassi A, Lazaroski S, Wu G et al (2014) Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels. J Allergy Clin Immunol 133:1410–1419CrossRefPubMedPubMedCentral

Scott K, Gadomski T, Kozicz T, Morava E (2014) Congenital disorders of glycosylation: new defects and still counting. J Inherit Metab Dis 37:609–617CrossRefPubMedPubMedCentral

Servián-Morilla ES, Takeuchi H, Lee TV et al (2016) A POGLUT1 mutation causes a muscular dystrophy with reduced notch signalling and satellite cell loss. EMBO Mol Med 8:1289–1309CrossRefPubMedPubMedCentral

Silveira C, Leal GF, Cavalcanti DP (2016) Desbuquois dysplasia type II in a patient with a homozygous mutation in XYLT1 and new unusual findings. Am J Med Genet Part A 170A:3043–3047CrossRef

Smith-Packard B, Myers SM, Williams MS et al (2015) Girls with seizures due to the c.320A>G variant in ALG13 do not show abnormal glycosylation pattern on standard testing. JIMD Rep 22:95–98CrossRefPubMedPubMedCentral

Stray-Pedersen A, Backe PH, Sorte HS et al (2014) PGM3 mutations cause a congenital disorder of glycosylation with severe immunodeficiency and skeletal dysplasia. Am J Hum Genet 95:1–12CrossRef

Tarailo-Graovac M, Sinclair G, Stöckler-Ipsiroglu S et al (2015) The genotypic and phenotypic spectrum of PIGA deficiency. Orphanet J Rare Dis 10:23CrossRefPubMedPubMedCentral

Taylan F, Costantini A, Coles N et al (2016) Spondyloocular syndrome: novel mutations in XYLT2 and expansion of the phenotypic spectrum. J Bone Miner Res 31:1577–1585CrossRefPubMed

Tham E, Eklund EA, Hammarsjö A et al (2015) A novel phenotype in N-glycosylation disorders: Gillessen-Kaesbach-Nishimura skeletal dysplasqia due to pathogenic variants in ALG9. Eur J Hum Genet 24:198–207CrossRefPubMedPubMedCentral

Van Damme T, Gardeitchik T, Mohamed M et al (2016) Mutations in ATP6V1E1 or ATP6V1A cause autosomal-recessive cutis laxa. Am J Hum Genet. doi:10.1016/j.ajhg.2016.12.010

Van Scherpenzeel M, Willems E, Lefeber DJ (2016) Clinical diagnostics and therapy monitoring in the congenital disorders of glycosylation. Glycoconj J 33:345–358CrossRefPubMedPubMedCentral

Varki A, Cummings RD, Aebi M et al (2015) Symbol nomenclature for graphical representations of glycans. Glycobiology 25:1323–1324CrossRefPubMedPubMedCentral

Vogt G, Vogt B, Chuzhanova N, Julenius K, Cooper DN, Casanova JL (2007) Gain-of-glycosylation mutations. Curr Opin Genet Dev 17:245–251CrossRefPubMed

Wada Y (2016) Mass spectrometry of transferrin and apolipoprotein C-III for diagnosis and screening of congenital disorder of glycosylation. Glycoconj J 33:297–307CrossRefPubMed

Willems AP, van Engelen BGM, Lefeber DJ (2016) Genetic defects in the hexosamine and sialic acid biosynthesis pathway. Biochim Biophys Acta 1860:1640–1654CrossRefPubMed

Zhang Y, Yu X, Ichikawa M et al (2014) Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment. J Allergy Clin Immunol 133:1400–1409CrossRefPubMedPubMedCentral

Zhang W, James PM, Ng BG et al (2016) A novel N-tetrasaccharide in patients with congenital disorders of glycosylation, including asparagine-linked glycosylation protein 1, phosphomannomutase 2, and mannose phosphate isomerase deficiencies. Clin Chem 62:208–217CrossRefPubMed

Title: What is new in CDG?
Authors: Jaak Jaeken
Romain Péanne
Publication date: 01-07-2017
Publisher: Springer Netherlands
Published in: Journal of Inherited Metabolic Disease / Issue 4/2017
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-017-0050-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2017

Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I

News and views

News and views

Inherited disorders of transition metal metabolism: an update

Recent advances in liver transplantation for metabolic disease

Amino acid synthesis deficiencies

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage